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Race and Beta-Blocker Survival Beneﬁt in Patients With Heart Failure:
An Investigation of Self-Reported Race and Proportion of African
Genetic Ancestry
Jasmine A. Luzum, PharmD, PhD, BCPS; Edward Peterson, PhD; Jia Li, PhD; Ruicong She, MS; Hongsheng Gui, PhD; Bin Liu, MPH;
John A. Spertus, MD, MPH; Yigal M. Pinto, MD, PhD; L. Keoki Williams, MD, MPH; Hani N. Sabbah, PhD; David E. Lanfear, MD, MS

Background-—It remains unclear whether beta-blockade is similarly effective in black patients with heart failure and reduced
ejection fraction as in white patients, but self-reported race is a complex social construct with both biological and environmental
components. The objective of this study was to compare the reduction in mortality associated with beta-blocker exposure in heart
failure and reduced ejection fraction patients by both self-reported race and by proportion African genetic ancestry.
Methods and Results-—Insured patients with heart failure and reduced ejection fraction (n=1122) were included in a prospective
registry at Henry Ford Health System. This included 575 self-reported blacks (129 deaths, 22%) and 547 self-reported whites (126
deaths, 23%) followed for a median 3.0 years. Beta-blocker exposure (BBexp) was calculated from pharmacy claims, and the
proportion of African genetic ancestry was determined from genome-wide array data. Time-dependent Cox proportional hazards
regression was used to separately test the association of BBexp with all-cause mortality by self-reported race or by proportion of
African genetic ancestry. Both sets of models were evaluated unadjusted and then adjusted for baseline risk factors and betablocker propensity score. BBexp effect estimates were protective and of similar magnitude both by self-reported race and by
African genetic ancestry (adjusted hazard ratio=0.56 in blacks and adjusted hazard ratio=0.48 in whites). The tests for interactions
with BBexp for both self-reported race and for African genetic ancestry were not statistically signiﬁcant in any model (P>0.1 for all).
Conclusions-—Among black and white patients with heart failure and reduced ejection fraction, reduction in all-cause mortality
associated with BBexp was similar, regardless of self-reported race or proportion African genetic ancestry. ( J Am Heart Assoc.
2018;7:e007956. DOI: 10.1161/JAHA.117.007956.)
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T

he landmark clinical trials that established the efﬁcacy of
beta-blockers in patients with heart failure (HF) with
reduced ejection fraction (HFrEF) predominately consisted of
white patients (80–99%),1–6 despite evidence that black
patients have higher risk for developing and dying from HF.7
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Subgroup analyses of these pivotal trials show effect
estimates that are consistent with treatment beneﬁt across
races (though very limited in terms of power),8,9 and
consensus guidelines reasonably recommend beta-blocker
use in all patients with HFrEF unless contraindicated.10 The
extrapolation of clinical trial data from 1 patient race to
another is an important issue because at least 29 medications
(including beta-blockers) are reported to have racial disparities in safety or efﬁcacy,11 and this is clearly salient in the
setting of HF.12 BEST (Beta Blocker Evaluation of Survival
trial), which tested bucindolol in chronic HFrEF patients,
showed differing effects depending on race with a trend
toward harm among black patients.13,14 Moreover, some
observational data sets have suggested reduced efﬁcacy of
approved beta-blockers in black HFrEF patients.15,16
A complicating issue surrounding race-based analyses is
that race is a subjective social construct associated with a
myriad of demographic, socioeconomic, comorbidity, and
treatment differences that can confound estimates of treatment beneﬁt.17 Moreover, it is imperfectly linked to genetic
Journal of the American Heart Association
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What Is New?
• Previous research suggested racial differences in betablocker effectiveness for treating heart failure with reduced
ejection fraction by self-reported race.
• We re-examined beta-blocker effectiveness by self-reported
race and by genetic ancestry to help distinguish biological
differences by race (ie, the genetic component) from
nonbiological components/correlates of race (eg, diet,
socioeconomic status, and others).
• We found that beta-blocker treatment was associated with a
similar reduction in the risk for mortality in self-identiﬁed
blacks compared with whites, regardless of genetic ancestry
(overall proportion African genetic ancestry).

What Are the Clinical Implications?
• This study provides strong reassurance that there is similar
beneﬁt of beta blockade in blacks with heart failure and
reduced ejection fraction compared with white counterparts.

Downloaded from http://ahajournals.org by on December 9, 2019

ancestry, which could indicate biological bases for difference
in therapeutic responses, both risks and beneﬁts. There are
signiﬁcant data suggesting that genetic variation, speciﬁcally
many variants that are correlated to ancestral population, may
also impact beta-blocker effectiveness or HF disease
progression.18–21 Unraveling the limitations of these past
reports of racial disparities in beta-blocker efﬁcacy among
HFrEF patients requires genetic ancestry data that can objectively and quantitatively assess ancestral background. It is
particularly important to include genetic ancestry in racial
analyses because self-reported race can substantially disagree
with genetic ancestry, especially in genetically admixed populations such as in the United States. For example, self-reported
blacks tend to average 20% European genetic ancestry, but
this ranges widely from near zero to majority European genetic
ancestry.11,22 To help evaluate the effectiveness of beta-blocker
use in blacks, as compared with whites, we developed a genetic
HF registry and compared the association between betablocker exposure (BBexp) and risk for all-cause mortality
between self-identiﬁed whites and blacks, and then also tested
the beta-blockers’ associations with all-cause mortality by
proportion of African genetic ancestry.

Methods

sensitive nature of this research, the data, analytical methods,
and study materials will not be made available to other
researchers for purposes of reproducing the results or
replicating the procedure. Patients for this study came from
a prospective genetic registry of HF patients with the overall
goal of discovering novel ways to better predict prognosis and
response to HF treatments. The registry started in October
2007 and completed in March 2015 at the Henry Ford Health
System, which is a vertically integrated health system serving
the primary and specialty healthcare needs of individuals in
southeastern Michigan. The health system includes several
hospitals, a multispecialty physician group of 1200 physicians, as well as an afﬁliated insurance product (Health
Alliance Plan; all subjects are members). Patients were
included in the HF registry if they were aged ≥18 years,
insured, and met the deﬁnition for HF as deﬁned by the
Framingham Heart Study.23 Speciﬁcally, patients must have
had at least 2 major, or 1 major and 2 minor, HF criteria
present at the time of exam or documented in the medical
record. Major criteria were paroxysmal nocturnal dyspnea or
orthopnea, neck vein distension, rales, cardiomegaly, acute
pulmonary edema, S3 gallop, increased venous pressure
(16 cm of water), circulation time (≥25 seconds), and hepatojugular reﬂux. Minor criteria were ankle edema, night cough,
dyspnea on exertion, hepatomegaly, pleural effusion, vital
capacity decreased 33% from maximum, and heart rate
≥120 beats per minute. Weight loss ≥4.5 kg in 5 days in
response to treatment was a major or minor criterion. Patients
were excluded from the registry if they were on dialysis or
dependent on supplemental oxygen or dialysis. Detailed
phenotypic information (eg, demographics, physical examination, past medical history, laboratory values, functional status,
and medications) and blood samples were collected upon
enrollment into the HF registry. Patient deaths were collected
from the Social Security Administration Death Master File,
Michigan State Division of Vital Records, and the Henry Ford
Health System administrative data, through July 28, 2016. Only
patients with HFrEF were included in this analysis. Patients
with left ventricular ejection fraction (LVEF) <50% veriﬁed by
echocardiography, nuclear stress tests, or radionuclide blood
pool imaging were included in the primary analysis (n=1122).
This ejection fraction cutoff was chosen to reﬂect patients with
systolic HF because the study was designed and started before
the more-recent reclassiﬁcations, suggesting that HFrEF
should be deﬁned as an LVEF ≤40%.24 To address whether
this could alter our ﬁndings, we performed a secondary
analysis restricted to patients with LVEF ≤40% (n=794).

Patient Data
The study was approved by the Institutional Review Board at
the Henry Ford Health System, and all patients gave written
informed consent before participation. Because of the
DOI: 10.1161/JAHA.117.007956

Calculation of BBexp
BBexp was calculated using dose standardization and pharmacy claims data as previously described.15 Brieﬂy, doses of
Journal of the American Heart Association
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Genotyping and Genetic Ancestry Analysis
Blood samples were collected at enrollment into the HF
registry and were immediately processed and stored at
70°C. Each sample was genotyped using the Axiom Biobank
array (Affymetrix, Santa Clara, CA), which includes the
following 600K genetic variants: (1) 300K genome-wide
variants with minor allele frequencies >1%; (2) 250K low
frequency (<1%) coding variants from global exome sequencing projects; and (3) an additional 50K variants to improve
African ancestry coverage (Yoruba in Ibadan, Nigeria [YRI]
booster). The proportion of West African genetic ancestry
(heretofore referred to as African ancestry) in each patient
was estimated using ANCESTRYMAP2.0.26 Brieﬂy, the software program uses a Hidden Markov Model to combine data
across unlinked single-nucleotide polymorphisms and incorporates information from many neighboring markers to infer
ancestry.

Statistical Analysis
Continuous baseline variables were summarized by the
meanSD and compared by self-reported race with 2-sample
DOI: 10.1161/JAHA.117.007956

Student t tests. Continuous baseline variables that were not
normally distributed were compared by self-reported race
using the 2-sample Mann–Whitney test. Categorical baseline
variables were summarized by counts and percentages and
compared by self-reported race using v2 tests or Fisher’s
exact tests, when appropriate. Time-dependent Cox proportional hazards regression models were used to assess the
relationship of BBexp with the primary end point of all-cause
mortality. BBexp was modeled as a continuous variable with a
daily value ranging from 0 (pharmacy claims indicated that no
beta-blocker was available to the patient on any day
throughout the 6 months preceding that day) to 1 (pharmacy
claims indicated that target doses of beta-blocker were
available to the patient on every day throughout the 6 months
preceding that day). Because BBexp was modeled as a
continuous variable, the hazard ratios (HRs) for the association between BBexp and all-cause mortality were scaled as
zero exposure (0) versus target exposure (1). BBexp was only
dichotomized when plotting survival curves (high exposure
deﬁned as ≥50th percentile and low exposure deﬁned as
<50th percentile). Two separate sets of models were made, 1
for self-identiﬁed race (dichotomous variable) and another for
genetic ancestry (continuous variable), that is, both factors
were not in models together. The 2 sets of models were
otherwise similar (ie, same covariates and end points).
Interaction between either self-reported race or proportion
of genetic African ancestry and BBexp was tested by
incorporating a multiplicative interaction term within the
models for time to all-cause mortality (eg, self-identiﬁed
race9BBexp). Models stratiﬁed by self-identiﬁed race were
also developed. The models were adjusted for the MetaAnalysis Global Group in Chronic Heart Failure (MAGGIC) risk
score27 (excluding beta-blocker as an input variable),
N-terminal pro-b-type natriuretic peptide level, and betablocker propensity score. Beta-blocker propensity score was
calculated using logistic regression of all variables in Table 1
with the output separated into quartiles and used as an
ordinal (1–4) adjuster in the Cox regression models.28 For
main effects, P<0.05 was considered statistically signiﬁcant,
and for the interaction, P<0.1 was considered statistically
signiﬁcant. In the analyses stratiﬁed by self-reported race, we
estimated 80% power to detect an HR ≤0.65 for beta-blocker
response, which is similar to the reduction in the risk for
mortality reported in the landmark beta-blocker clinical trials.
The primary analysis of African genetic ancestry included
genetic ancestry as a continuous variable, which was available
in all subjects, and thus there was similar power for the
analysis of African genetic ancestry and beta-blocker survival
beneﬁt. However, when race was stratiﬁed by African genetic
ancestry <5% and >80%, subjects with African genetic
ancestry between 5% and 80% were excluded (n=27 selfreported whites and n=165 self-reported blacks excluded).
Journal of the American Heart Association
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speciﬁc beta-blockers were standardized into dose equivalents by the target dose used in clinical trials of HFrEF or, for
beta-blockers not tested in HF clinical trials (eg, atenolol), by
the maximum daily dose. Speciﬁcally, these target/maximal
daily doses were 50 mg for carvedilol, 200 mg for metoprolol
(for both long-acting and short-acting formulations), 10 mg
for bisoprolol, 100 mg for atenolol, and 600 mg for labetalol.
For example, 25 mg of carvedilol per day (ie, 12.5 mg twicedaily) was considered a 0.5 beta-blocker standardized dose
equivalent. Carvedilol (39%) and metoprolol succinate (38%)
were the agents most often used, but there were smaller
groups of patients using metoprolol tartrate (18%) or another
beta-blocker (4%).
BBexp was then calculated by multiplying the standardized
dose equivalent by the quantity of medication dispensed in a
6-month time block, divided by the total number of days in the
6-month time block. BBexp was calculated for each patient for
each day of observation, and thus this method accounts for
both dose and adherence over a rolling period of time
(6 months). For example, if a patient was prescribed 12.5 mg
of carvedilol twice-daily and had picked up their prescription
from the pharmacy so that there was continuous availability
over the previous 6 months, then their calculated BBexp
would be 0.5. We have previously demonstrated that this
approach for calculating BBexp is superior to a single time
point and dichotomous classiﬁcation of BBexp (eg, discharge
medication status), in terms of correlation to heart rate and
death or hospitalization.25

Heart Failure Beta-Blocker Beneﬁt by Race
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Proportion of African Genetic
Ancestry

Self-Reported Race
Overall
(n=1122)

Characteristic

Black (n=575)
51%

White (n=547)
49%

P Value*
‡

>80% (n=410)
37%

<5% (n=520)
46%

P Value†

171 (41.7%)

153 (29.4%)

<0.001‡

Female

394 (35.1%)

231 (40.2%)

163 (29.8%)

<0.001

Age, y

67.511.9

64.412.1

70.810.8

<0.001‡

63.811.8

70.710.8

<0.001‡

LVEF, %

34.711.1

33.411.5

36.110.5

<0.001‡

32.711.3

36.110.4

<0.001‡

Ischemic etiology

494 (44.0%)

192 (33.4%)

302 (55.2%)

<0.001‡

124 (30.2%)

295 (56.7%)

<0.001‡

383 (93.4%)

442 (85.0%)

<0.001‡

87 (21.2%)

121 (23.3%)

0.456

123 (30.0%)

84 (16.2%)

<0.001‡

76 (18.5%)

188 (36.2%

<0.001‡

53 (12.9%)

60 (11.5%)

0.520

189 (46.1%)

193 (37.1%)

0.006‡

31.37.7

30.87.1

0.301

131.724.2

125.921.5

<0.001‡

Hypertension

977 (88.91%)

530 (92.2%)

467 (85.4%)

<0.001

Chronic obstructive pulmonary disease

246 (21.9%)

118 (20.5%)

128 (23.4%)

0.244

Chronic kidney disease

251 (22.4%)

158 (27.5%)

93 (17.0%)

<0.001

‡
‡

Atrial fibrillation

311 (27.7%)

113 (19.7%)

198 (36.2%)

<0.001

Stroke/transient ischemic attack

140 (12.5%)

74 (12.9%)

66 (12.1%)

0.684

Diabetes mellitus
Body mass index, kg/m

2

‡

462 (41.21%)

260 (45.2%)

202 (36.9%)

0.005

31.17.3

31.47.6

30.87.1

0.198

‡

‡

Systolic blood pressure, mm Hg

12923

131.224.0

126.621.7

0.001

Heart rate, beats per min

71.213.1

72.313.3

69.912.8

0.002‡

73.113.6

70.012.4

<0.001‡

NTpro-BNP, pmol/L

358380

353394

364366

0.635

354392

360363

0.812

Serum creatinine, mg/dL

1.280.92

1.381.12

1.180.60

0.001‡

1.451.27

1.170.61

<0.001‡

MAGGIC risk score (w/o beta-blocker)

17.87.3

17.37.5

18.47.1

0.010‡

17.47.7

18.47.2

0.045‡

BBexp

26.629.0

26.428.5

26.729.6

0.852

26.029.0

27.036.0

0.626

Any BBexp

781 (76.9%)

401 (76.2%)

380 (77.6%)

0.619

280 (74.7%)

363 (77.7%)

0.298

ACE/ARB exposure

616 (54.9%)

331 (57.6%)

285 (52.1%)

0.066

238 (58.1%)

272 (52.3%)

0.081
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‡

Proportion African genetic ancestry

43.444.0

83.520.4

1.06.6

<0.001

NA

NA

NA

Length of follow-up, d

1089699

1082695

1097703

0.737

1090708

1109708

0.699

Deaths

255 (22.7%)

129 (22.4%)

126 (23.0%)

0.811

92 (22.4%)

115 (22.1)

0.906

ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BBexp, beta-blocker exposure; LVEF, left ventricular ejection fraction; MAGGIC, Meta-Analysis
Global Group in Chronic Heart Failure risk score27; NA, not applicable; NTpro-BNP, N-terminal pro-b-type natriuretic peptide.
*P value for self-reported black vs white.
†
P value for >80% African genetic ancestry vs <5% African genetic ancestry.
‡
P<0.05.

However, the estimated power only decreased slightly when
race was stratiﬁed by African genetic ancestry (but not
when African genetic ancestry was used as a continuous
variable) to have 80% power to detect an HR ≤0.63 for
beta-blocker survival beneﬁt. All statistical analyses were
performed in SAS software (version 9.4; SAS Institute Inc,
Cary, NC).

Results
The analytical cohort comprised 1122 HFrEF patients meeting
inclusion criteria: 575 self-reported black patients (51%) and
547 self-reported white patients (49%). The overall group had
a median follow-up of 1089 days (range, 3–3516). There were
a total of 255 deaths in the analysis, 129 among black
DOI: 10.1161/JAHA.117.007956

patients (22%) and 126 in white patients (23%). Baseline
characteristics overall and stratiﬁed by self-reported race are
presented in Table 1. Statistically signiﬁcant differences at
baseline were present between the groups for many characteristics, including age, sex, ischemic etiology, LVEF, and atrial
ﬁbrillation. Notably, there were no signiﬁcant differences
between race groups in terms of medication exposure,
speciﬁcally including quantiﬁed BBexp, categorized BBexp
(none versus any), or categorized angiotensin-converting
enzyme inhibitor or angiotensin receptor blockers. Genetic
admixture was observed in the cohort within both race
groups, but was more prominent in self-identiﬁed blacks
(Figure 1). Self-reported whites had an average of 1% African
genetic ancestry, whereas self-reported blacks had an average of 16% European genetic ancestry.
Journal of the American Heart Association
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Table 1. Baseline Characteristics Overall and Stratiﬁed by Both Self-Reported Race and Proportion of African Genetic Ancestry
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Figure 1. Proportion of African genetic ancestry in the self-reported whites (left panel) and blacks (right panel). YRI indicates Yoruba in Ibadan,
Nigeria.

Downloaded from http://ahajournals.org by on December 9, 2019

Overall, the quantiﬁed beta-blocker exposure metric
(BBexp) varied from 0% to 100% across the cohort and over
time. Figure 2 depicts the mean BBexp for each individual
from least to most across the cohort. Roughly 25% of patients
had no BBexp, whereas 55% had intermediate levels of BBexp
and 20% had relatively high-intensity BBexp. In the overall
cohort, BBexp was associated with improved survival. Unadjusted analysis revealed BBexp HR of 0.47 (P=0.001). When
adjusted for baseline Meta-Analysis Global Group in Chronic
Heart Failure (MAGGIC) score (without the beta-blocker
variable input), N-terminal pro-b-type natriuretic peptide, and
self-reported race (race is not a component of MAGGIC) the
BBexp continued to be strongly protective with an adjusted
HR (aHR) of 0.49 (P=0.005).

Beta-Blocker Association With Time to Death by
Self-Identiﬁed Race and Genetic Ancestry
We tested Cox models of BBexp on the time to death in
univariable analysis and then analyses adjusted for baseline
MAGGIC score (minus beta-blocker input). In unadjusted
analyses stratiﬁed by race, BBexp was strongly protective in
both groups, though showing some numeric separation.
Among white patients, BBexp HR was 0.41 (95% conﬁdence
interval, 0.22, 0.76; P=0.005), whereas in black patients the
HR was 0.55 (95% conﬁdence interval, 0.31, 0.98; P=0.041).
Once adjusted for baseline risk using MAGGIC score alone,
the HRs in each group were more closely aligned. For whites,
the BBexp aHR was 0.45 (0.24, 0.86; P=0.016), whereas for

Figure 2. Mean beta-blocker exposure metric (BBexp, Y axis) for each participant across the
cohort (X axis).

DOI: 10.1161/JAHA.117.007956
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BBexp9African Genetic
Ancestry
0.642
b=0.21
BBexp9self-reported race
BBexp9race

0.88 (0.78, 0.99)
BB propensity

BB indicates beta-blocker; BBexp, beta-blocker exposure; CI, conﬁdence interval; HR, hazard ratio; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure risk score27; NA, not applicable; NTpro-BNP, N-terminal pro-b-type natriuretic
peptide (HR scaled by 400 units).
*P<0.05.

0.823
b=0.11

0.781
0.97 (0.80, 1.18)
0.003*
0.76 (0.63, 0.91)
0.933
1.01 (0.85, 1.19)
0.003*
0.76 (0.64, 0.91)

1.11 (1.09, 1.13)
MAGGIC

0.038*

0.001*

0.002*
1.39 (1.13–1.70)

1.10 (1.07, 1.14)
0.001*

0.001*
1.58 (1.31, 1.80)

1.12 (1.08, 1.15)
0.001*

0.001*
1.38 (1.18, 1.60)

1.11 (1.07, 1.14)
0.001*

0.001*
1.55 (1.30, 1.84)
1.47 (1.32, 1.65)
NTpro-BNP

0.001*

1.11 (1.08, 1.15)

NA
NA
NA
NA
0.95 (0.70, 1.31)
Black

0.765

0.46 (0.24, 0.89)
BBexp

0.001*

0.045*
0.47 (0.23, 0.98)
0.022*
0.45 (0.23, 0.89)
0.062
0.56 (0.31, 1.03)
0.029*
0.48 (0.25, 0.93)

P Value
Black HR (95% CI)
n=575
P Value
P Value
All Patients HR (95% CI)
n=1122
Variable

0.020*

>80% HR (95% CI)
n=410
<5% HR (95% CI)
n=520
White HR (95% CI)
n=547

P Value

Proportion of African Genetic Ancestry

We performed several secondary analyses to assess whether
our results were impacted by certain potential confounders or
classiﬁcation schemes. First, because this was an observational study, confounding by indication or disease severity is
always a concern. The primary analysis plan included
adjustment for baseline risk by using a validated clinical risk
score (MAGGIC). To supplement this, we additionally tested
models adjusted for baseline N-terminal pro-b-type natriuretic
peptide levels and propensity for beta-blocker use. In terms of
overall beta-blocker effect, when including propensity as the
only covariate, the BBexp effect remains very consistent with
the unadjusted overall analysis (aHR of 0.50; P=0.002). The
results were also similar in models adjusted for MAGGIC, race,
N-terminal pro-b-type natriuretic peptide, and propensity
(Table 2). Importantly, in the full model, the race9BBexp
interaction remains insigniﬁcant (b=0.21; P=0.64), race was
not a signiﬁcant predictor of outcome, and in the racestratiﬁed models the BBexp aHR were relatively similar (BBexp
aHR 0.48 for whites and 0.56 blacks), with the estimates for
each race group indicating a strong protective association.
To address potential concerns regarding the fact that
ejection fraction <50% was part of the inclusion criteria (as
opposed to ≤40%), we performed additional analyses

Self-Reported Race

Downloaded from http://ahajournals.org by on December 9, 2019
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black patients the aHR was 0.54 (0.30, 0.97; P=0.038), again
statistically signiﬁcant in both groups. Formal testing for the
interaction of race with BBexp (ie, adding race9BBexp term in
the model) was also not signiﬁcant (b=0.17; P=0.70). The
relationship of BBexp to survival, stratiﬁed by race, is
presented in Table 2 and illustrated in Figure 3.
We then sought to examine whether genetic ancestry, a
better reﬂection of genetic differences across race (rather than
self-identiﬁed race), modulated the association of BBexp with
survival times. Speciﬁcally, we estimated proportion of African
ancestry for each individual and then tested similar timedependent Cox models as above, but with proportion of African
genetic ancestry included as a numerical covariate and with
interaction terms. The BBexp effect did not appear to differ
across the spectrum of African genetic ancestry. In models
including BBexp, MAGGIC, and proportion African genetic
ancestry, genetic ancestry was not statistically signiﬁcant
(P=0.77), and the BBexp effect estimate was similar to the
above (aHR=0.50; P=0.002). Formal testing with interaction
term (BBexp9ancestry) was also not statistically signiﬁcant
(P=0.71). To better illustrate this lack of impact of African
genetic ancestry on beta-blocker effectiveness, if the BBexp HR
is tabulated using a proportion African genetic ancestry of <5%
versus >80%, the unadjusted HR generated are 0.70 and 0.72,
respectively. A comparison of HRs for high versus low BBexp in
each race category is presented in Table 3.

P Value

Luzum et al

Table 2. Association of BBexp With Time to All-Cause Mortality in All Patients and Stratiﬁed by Both Self-Reported Race and Proportion of African Genetic Ancestry
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Figure 3. Survival curves stratiﬁed by self-reported race and high vs low beta-blocker (BB) exposure. High
beta-blocker exposure was deﬁned as ≥50th percentile (dashed lines) and low beta-blocker exposure as
<50th percentile (solid lines). Red lines are self-reported blacks and blue lines are self-reported whites.
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restricted to those patients with LVEF ≤40%. Among the 1122
total subjects, 794 had ejection fraction ≤40% (n=370 white
patients and n=424 black patients). In these subgroups, the
BBexp HR was 0.58 (P=0.14) and 0.59 (P=0.09) for whites
and blacks, respectively. In the full model of all patients with
ejection fraction ≤40% (n=717) adjusted for MAGGIC, race,
and race9BBexp interaction, the BBexp HR was 0.61 (0.38,
0.98; P=0.040) and the interaction was not signiﬁcant
(P=0.78).

Discussion
Deﬁnitive evidence for the efﬁcacy of beta-blockers in blacks
with HFrEF will likely never be obtained given that the pivotal

trials did not include a sufﬁcient number of such participants
and further randomized trials would likely be deemed
unethical. Whereas the preponderance of evidence suggests
a strong beneﬁt, this prospective, observational study extends
past studies by both using self-reported race as a potential
marker of a cluster of factors that differ and genetic ancestry
as a quantiﬁable and objective biological construct. For
example, if we had found a signiﬁcant difference in betablocker response by self-reported race and not genetic
ancestry, then that could have suggested that the difference
is likely attributed to sociocultural differences rather than
biological. The fact that we found similar reductions in
mortality stratiﬁed by self-reported race (representative of
biological+sociocultural effects) and genetic ancestry (representative of only biological effects) is reassuring that beta-

Table 3. HRs and 95% CIs for High Beta-Blocker Exposure (≥50th Percentile) versus Low Beta-Blocker Exposure (<50th Percentile)
in the Self-Reported Races and Patients With <5% and >80% Proportion African Genetic Ancestry
Race Category
Self-Report

Genetic

BBexp

White

Black

<5% African

>80% African

High vs low

n=516
0.74 (0.52–1.06)
P=0.102

n=543
0.69 (0.49–0.99)
P=0.045*

n=490
0.71 (0.49–1.03)
P=0.071

n=388
0.64 (0.42–0.98)
P=0.038*

Interaction P value

P=0.979

P=0.992

All models were adjusted for MAGGIC risk score (minus beta-blocker) and NTpro-BNP level, and the sample sizes were for patients with complete data available for analysis. BBexp
indicates beta-blocker exposure; CI, conﬁdence interval; HR, hazard ratio; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure risk score27; NTpro-BNP, N-terminal pro-b-type
natriuretic peptide.
*indicates P < 0.05.
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agents concur with our current observations.31,32 The
contrast with our previous data is most likely attributed to
differences in the end point used. Our previous work utilized a
composite end point including hospitalization, and indeed
when examining our previous data, the differences between
racial groups were driven primarily by hospitalization.15 Allcause mortality alone (used in this prospective study) may be
a better end point than the composite end point of all-cause
mortality+hospitalization (used in our previous, retrospective
study) for evaluating beta-blocker efﬁcacy. Hospitalization of
HF patients is inﬂuenced by factors that are unrelated to betablocker efﬁcacy more than all-cause mortality, such as patient
refusal, lack of available beds, the number of cardiologists,
whether the patient came to the hospital from home or a
skilled nursing facility, and even the day of the week.33–36
Ultimately, hospitalization is the discretion of the treating
physician in the emergency room or clinic. Beta-blockers
decreased the risk of hospitalization in the landmark clinical
trials, but as noted previously, the enrollment of blacks in the
landmark clinical trials was extremely low. Recent data show
that hospitalization rates signiﬁcantly differ by race,34 and
thus inclusion of hospitalization in the end point may
confound the results in race-stratiﬁed analyses such as this
study.
An additional strength of this study was the inclusion of
genetic ancestry to explore more biologically based mechanisms of potential racial differences in beta-blocker effectiveness. This is an important consideration because of the
known and signiﬁcant genetic admixture in the United
States,17 as well as the complexity of self-identiﬁed race as
a social construct. The availability of genetic ancestry can
help differentiate true inherited differences versus the wide
range of environmental factors that are associated with selfidentiﬁed race, such as socioeconomic status, diet, and
healthcare quality and accessibility, all of which can make
attempts to understand the underlying cause of race disparities in health outcomes very difﬁcult.37 It is important to
interrogate the role of genetic ancestry because socioeconomic factors do not fully explain the critical race disparities
in HF outcomes,38 and to try to quantify potential genetic and
biological effects. For example, African genetic ancestry is
associated with poorer diastolic function parameters in HF
patients.39 Consistent with the literature, substantial genetic
admixture was observed in our patient population, and despite
the potential for differences in outcomes in self-reported race
versus genetically deﬁned ancestry, the reduction in the risk
for mortality from beta-blockers in our study was mostly
similar across the entire spectrum. The fact that even
quantiﬁed African genetic ancestry proportion, a granular
marker of genetic race, was also not associated with
differences in beta-blocker beneﬁt provides some additional
reassurance of equal effectiveness in blacks.
Journal of the American Heart Association
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blockers are equally effective in white and black patients. We
found a marked reduction in mortality associated with betablocker treatment that was similar in blacks and whites,
regardless of race or genetic ancestry. Compared with the
landmark trials for HF-approved beta-blockers, our study
includes roughly the same number of black patients (n=575)
as the number of black patients in the MERIT-HF (Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart
Failure), US Carvedilol Trial, COPERNICUS (Carvedilol
Prospective Randomized Cumulative Survival Trial), and
CIBIS-II (second Cardiac Insufﬁciency Bisoprolol Study) combined (n=546). The BEST trial of the non–US Food and Drug
Administration–approved bucindolol included 627 black
patients, but treatment with bucindolol trended toward
increased all-cause mortality in the black patients and a
signiﬁcant test for interaction of treatment beneﬁt with
patient race, further supporting the importance of this racestratiﬁed analysis. This study is the ﬁrst to examine this issue
by quantiﬁed genetic ancestry, which can potentially offer a
more-granular view of the biological portion of race. Previous
studies on the genetic differences in beta-blocker response
have relied on candidate gene approaches, particularly
candidate polymorphisms affecting adrenergic activity.29
Adverse genetic polymorphisms in the adrenergic system
that are associated with decreased beta-blocker response are
most frequent in blacks. The strength of our approach using
whole-genome ancestry informative markers is that it captures ancestral variation across the entire genome, and it
accounts for population substructure, a well-known phenomenon that confounds genetic association studies.30
Our data provide additional insight in the context of past
literature. Our ﬁndings are similar to previous observational
studies investigating racial differences in beta-blocker
response in HF patients,16 which found protective, though
nonsigniﬁcant, HRs for mortality, similar to the clinical trial
data for carvedilol and metroprolol succinate in blacks. Our
data show a signiﬁcant beneﬁt in blacks, and add a major
advantage compared with previous observational studies, in
that we utilized time-dependent quantiﬁed BBexp calculated
from pharmacy claims. This method is a far more-granular and
sensitive way of quantifying drug exposure (accounts for
adherence, dose variability, and changes over time) compared
with dichotomized baseline classiﬁcation schemes, which
were usually used in the previous studies. Our data do
contrast with the BEST trial ﬁndings, as well as our previous
retrospective study,15 which yielded a statistically signiﬁcant
race interaction for beta-blocker–associated beneﬁt (ie,
increased beta-blocker beneﬁt in whites compared with
blacks for the composite end point of all-cause mortality
plus hospitalization). Given the totality of data, the BEST
ﬁndings seem most easily explained as an agent-speciﬁc
effect, given that several studies with the other beta-blocking
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Our study should be interpreted in the context of the following
potential limitations. Whereas an observational study can never
deﬁnitively assess absolute efﬁcacy such as in a clinical trial, we
have taken great care to adjust for potential confounders. We
sought to mitigate confounders inherent in observational study
design by adjusting with several methods, including a comprehensive and previously validated clinical score, a biomarker,
and a beta-blocker propensity score. Supporting our external
validity is that the beta-blocker beneﬁt estimates were similar
to those expected from clinical trials, and overall were
statistically signiﬁcant. Another limitation of our study was
that beta-blockers approved speciﬁcally for HF (ie, carvedilol,
metoprolol succinate, and bisoprolol) were not distinguished
from other beta-blockers. However, of the patients who were
taking beta-blockers at baseline, the vast majority (78%) were
taking HF-approved agents; the most frequent nonapproved
agent being metoprolol tartrate (18%), and only 4% of patients
taking some other beta-blocker. Despite inclusion of other
beta-blockers and low beta-blocker treatment rate, an advantage of this observational study design is that it more closely
represents current, real-world clinical practice than the older
randomized controlled trials. Moreover, a range of beta-blocker
treatment (from zero, to low, to target exposure) allows analysis
of beta-blocker beneﬁt, which would not be possible if all
patients were treated with target doses of beta-blockers. Even
with inclusion of other beta-blockers, our results are reassuring
given that overall the beta-blocker survival beneﬁt was
statistically signiﬁcant in both groups and of a magnitude
which approximates the ﬁndings from randomized trials of
approved beta-blocking agents. Finally, our data are from
insured patients in a single health system, so although our
service population is diverse and reﬂects the greater regional
population,40 the fact that all patients had insurance and
access to care may somewhat limit the generalizability.

This research was supported by the National Heart, Lung, and
Blood Institute (Lanfear R01HL103871, R01HL132154; Williams R01HL118267; Sabbah P01HL074237, R01HL132154).
Dr Williams is also supported by the National Institute of Allergy
and Infectious Diseases (R01AI079139) and the National
Institute of Diabetes and Digestive and Kidney Diseases
(R01DK064695, R01DK113003). Dr Luzum was supported by
the NIH student loan repayment program (L30 HL110279).

Conclusions
Our prospective, observational study demonstrates that betablocker–associated reduction in the risk for mortality in HFrEF
patients is similar between self-reported black race and
genetically assigned African race, as compared with whites.
We further demonstrate that the overall proportion of African
genetic ancestry, deﬁned by genome-wide ancestry informative markers, does not modify the beta-blocker beneﬁt. These
data lend further credence to current guidelines that recommend beta-blocker use in all HFrEF patients, reassuring
patients and providers that black HFrEF patients are likely
deriving similar beneﬁt from beta-blocker treatment. These
ﬁndings are not suggestive of genetic mechanisms meaningfully impacting beta-blocker effectiveness relative to race.
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